Literature DB >> 19372724

Branch retinal vein occlusion: classification and treatment.

Maurizio Battaglia Parodi1, Francesco Bandello.   

Abstract

Branch retinal vein occlusion (BRVO) refers to a heterogeneous group of disorders with different clinical aspects, courses, and probably therapy. Depending on the site of the arteriovenous crossing, we can roughly divide BRVO into 3 main groups: major BRVO, hemispheric retinal vein occlusion, and macular BRVO. Main treatment options include laser treatment, corticosteroid administration, anti-VEGF drugs, and sheathotomy with or without vitrectomy. Laser photocoagulation, as demonstrated by the Branch Vein Occlusion Study, represents the gold standard for the treatment of macular edema and ocular neovascularization following BRVO. The limited functional outcomes achievable by means of laser treatment have prompted researchers to try alternative options, with varying results. The recent introduction of combined therapies for macular edema may provide a superior approach in an attempt to improve and stabilize visual acuity over a long-term follow-up. (c) 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372724     DOI: 10.1159/000213640

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  18 in total

1.  Prospective multicenter study of visual outcomes following three different treatments for macular edema associated with branch retinal vein occlusion: a study by the Japanese BRVO study group.

Authors:  Seiyo Harino; Kenichiro Bessho; Teruyo Kida
Journal:  Jpn J Ophthalmol       Date:  2012-02-23       Impact factor: 2.447

2.  Semiautomated intraocular laser surgery using handheld instruments.

Authors:  Brian C Becker; Robert A MacLachlan; Louis A Lobes; Cameron N Riviere
Journal:  Lasers Surg Med       Date:  2010-03       Impact factor: 4.025

3.  Effect of vitreomacular adhesion on antivascular endothelial growth factor therapy for macular edema secondary to branch retinal vein occlusion.

Authors:  Ryo Terao; Kentaro Yuda; Kayo Kure; Tatsuya Inoue; Hiroshi Ohtsu; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2014-01-10       Impact factor: 2.447

Review 4.  Cell-based therapies for diabetic retinopathy.

Authors:  Lynn C Shaw; Matthew B Neu; Maria B Grant
Journal:  Curr Diab Rep       Date:  2011-08       Impact factor: 4.810

Review 5.  [Retinal vein occlusion : Epidemiology, classification and clinical findings].

Authors:  N Feltgen; A Pielen
Journal:  Ophthalmologe       Date:  2015-07       Impact factor: 1.059

Review 6.  Clinical implications of retinal oximetry in retinal vein occlusion: a review.

Authors:  Aditya V Belamkar; Sayena Jabbehdari; Alon Harris; Amir R Hajrasouliha
Journal:  Acta Ophthalmol       Date:  2021-11-29       Impact factor: 3.988

7.  Study of retinal vessel oxygen saturation in ischemic and non-ischemic branch retinal vein occlusion.

Authors:  Lei-Lei Lin; Yan-Min Dong; Yao Zong; Qi-Shan Zheng; Yue Fu; Yong-Guang Yuan; Xia Huang; Garrett Qian; Qian-Ying Gao
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

8.  Hyperhomocysteinemia, a biochemical tool for differentiating ischemic and nonischemic central retinal vein occlusion during the early acute phase.

Authors:  Kapil Deb Lahiri; Somnath Mukherjee; Sambuddha Ghosh; Suman Mukherjee; Jayanta Dutta; Himadri Datta; Harendra Nath Das
Journal:  Korean J Ophthalmol       Date:  2015-03-17

Review 9.  Efficacy and safety of widely used treatments for macular oedema secondary to retinal vein occlusion: a systematic review.

Authors:  Julie Glanville; Jacoby Patterson; Rachael McCool; Alberto Ferreira; Kerry Gairy; Ian Pearce
Journal:  BMC Ophthalmol       Date:  2014-01-21       Impact factor: 2.209

10.  Incidence and Characteristics of Patients with Visual Impairment due to Macular Edema Secondary to Retinal Vein Occlusion in a Representative Canadian Cohort.

Authors:  Robert J Petrella; Julie Blouin; Brian Davies; Martin Barbeau
Journal:  J Ophthalmol       Date:  2012-10-14       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.